This study aims to investigate how much fractionation, and the different delivery dynamics of higher dose-per-fraction deliveries, can influence the impact of interplay effects for PBS-based lung tumour treatments.
Results:
For single fraction only delivery (shown by error bars with hollow markers in figure a), the normalized HIs are similar for the different fraction doses for both patients, with HI being typically 14/15% higher than the static for case I and II respectively. For the full treatments (solid markers), the normalized HIs of plans under scheme A and B are equal or better than for the static plan, with only ±1.2% variations as a function of starting phase. In addition, whereas for scheme C, HI is 2.5±2.6/4.8±2.3% (Case I/II) higher than the static case, this also reaches comparable homogeneity as the static case once combined with moderate rescanning (<5x). Variability is also reduced to within 1%, independent of the rescanning technique used. Concerning treatment time, for single fractions, nearly no difference can be seen among the different schemes when no rescanning is applied, due to the layer-wise optimized dose rate used by the ProBeam system. For 5x LS or VS, treatment time is increased by 100% and 37% respectively for scheme C in comparison to scheme A, although the absolute treatment time for LS is always less than half that of VS for all schemes. For the whole treatment, more than 75% reduction of time cost can be obtained once fractionation scheme (C) is used.
Conclusion:
For PBS-based lung tumour proton therapy, fractionation can lead to an improved target homogeneity, and variability as a function of starting phase is only obvious when large fraction doses are used and can be reduced with moderate (<5x) rescanning is applied.
